SCHEMBL24563

SCHEMBL24563

CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 1.00
NR5A2 O00482 1/20 1.00
NR5A1 Q13285 1/20 1.00
MAPT P10636 3/20 0.88
FABP3 P05413 1/20 0.78
RECQL P46063 1/20 0.77
ALDH1A1 P00352 1/20 0.68
ADRA1D P25100 1/20 0.66
PTAFR P25105 1/20 0.66
HTR1D P28221 1/20 0.66
HTR2C P28335 1/20 0.66
ADRA1B P35368 1/20 0.66
DRD3 P35462 1/20 0.66
TMEM97 Q5BJF2 1/20 0.66
LPAR3 Q9UBY5 3/20 0.63
LPAR1 Q92633 2/20 0.63
ENPP2 Q13822 1/20 0.63
MAPK1 P28482 3/20 0.60
MEN1 O00255 2/20 0.60
GMNN O75496 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimyristoylphosphatidylcholine SCHEMBL244839 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL10498112 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
Dimyristoylphosphatidylcholine SCHEMBL37475 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL234790 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL233046 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL22693933 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
Dimyristoylphosphatidylcholine SCHEMBL236969 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL231824 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL2036043 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3
Colfosceril Palmitate SCHEMBL2734250 1.00 SMN1; SMN2 (1.00) SMN1; SMN2NR5A2NR5A1MAPTFABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 20674 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144759-A1 Surface-modified plant-derived extracellular vesicles and targeted drug delivery system using the same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-05-28 US claimed
EP-4746913-A1 LIPID NANOPARTICLES COMPRISING POLYMER-CONJUGATED LIPIDS AND USES THEREOF Pfizer Inc. (US) 2026-05-27 EP claimed
EP-4746923-A2 DELIVERY SYSTEM COMPRISING LIPID OR POLYMERIC NANOPARTICLES COMPRISING THYROID HORMONES FONDAZIONE RICCARDO TERZI E SILVIO ALBINI (IT) 2026-05-27 EP claimed
EP-4746852-A1 LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION Universität Bern (CH) 2026-05-27 EP claimed
EP-4746859-A2 COMPOSITION AND METHOD FOR MAKING LIPID NANO-CARRIERS AND THE CORRESPONDING LIPID NANO-CARRIERS FOR BIOMEDICAL USE Università degli Studi di Salerno (IT) 2026-05-27 EP claimed
EP-4747263-A1 LIPID NANOPARTICLES AND USES THEREOF University of Connecticut (US) 2026-05-27 EP claimed
CN-121668297-B Broad-spectrum mRNA vaccine for preventing cat infectious peritonitis and preparation method thereof Ruipu Biotechnology Co.,Ltd. (CN) 2026-05-26 CN claimed
CN-122075516-A Application of PLAC8 as target in preparation of tumor treatment medicines 2026-05-26 CN claimed
US-12636252-B2 Process of preparing mRNA-loaded lipid nano particles TRANSLATE BIO, INC. (US) 2026-05-26 US claimed
CN-121758648-B Preparation method of alkylated lentinan and application of alkylated lentinan in LNP vaccine SHANDONG LUYE PHARMACEUTICAL CO.,LTD. (CN) 2026-05-26 CN claimed
US-6562316-B1 Stabilized liposomes transporting toxic substance to cell nucleus; increased uptake in tumors; reduced impact on healthy organs and tissues NUCLISOME AB (SE) 2003-05-13 US claimed
US-6241999-B1 SUBSTITUTING FIRST AMPHIPATHIC LIPID WITH ONE HAVING A SIMILIAR STRUCTURE BUT MORE C ATOMS SKYEPHARMA, INC. 2001-06-05 US claimed
US-6193998-B1 INCREASING EFFICIENCY USING MULTIVESICULAR LIPOSOMES CONTAINING PHOSPHOLIPIDS SKYEPHARMA INC. 2001-02-27 US claimed
US-6171613-B1 REPLACING AMPHIPATHIC LIPIDS SKYEPHARMA INC. 2001-01-09 US claimed
EP-1033972-A1 DRUG DELIVERY SYSTEM WITH TWO-STEP TARGETING Edwards, Katarina (SE) 2000-09-13 EP claimed
EP-0971699-A1 METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES SkyePharma Inc. (US) 2000-01-19 EP claimed
US-5997899-A INCREASING THE NUMBER OF CARBONS IN THE CARBON CHAIN OF AT LEAST ONE LIPID IN THE LIPID COMPONENT OF THE LIPOSOME, WHEREIN THE CHEMICAL STRUCTURES OF THE TWO LIPIDS ARE OTHERWISE SUBSTANTIALLY SIMILAR. SKYEPHARMA INC. (US) 1999-12-07 US claimed
WO-1999029302-A1 DRUG DELIVERY SYSTEM WITH TWO-STEP TARGETING EDWARDS KATARINA (SE) 1999-06-17 WO claimed
WO-1998033483-A1 METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES SKYEPHARMA, INC. (US) 1998-08-06 WO claimed
EP-0630231-B1 LIPOSOMES WITH EXCESS NEGATIVE CHARGE MAX PLANCK GESELLSCHAFT (DE) 1996-03-06 EP claimed